Non-randomized pilot study on the evaluation of the quality of life and psychosocial stress before and after systemic therapy in patients affected by moderate to severe psoriasis

Journal of Biological Regulators and Homeostatic Agents

Volumn 23, Issue 2, 2009, Pages 111-117

  Panigalli, S ^a   Coccarielli, D ^a   Germi, Lerica ^a   Trevisan, G P ^a   Veller Fornasa, C ^a  

^a SAN BORTOLO HOSPITAL   (Italy)

Author keywords

Psoriasis; Psoriasis life stress inventory; Psychosocial aspects; Quality of life; Therapy

Indexed keywords

EFALIZUMAB; ETANERCEPT; IMMUNOGLOBULIN G; IMMUNOSUPPRESSIVE AGENT; MONOCLONAL ANTIBODY; NONSTEROID ANTIINFLAMMATORY AGENT; TNFR FC FUSION PROTEIN; TNFR-FC FUSION PROTEIN; TUMOR NECROSIS FACTOR RECEPTOR;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; HUMAN; MALE; MENTAL STRESS; PSORIASIS; QUALITY OF LIFE; ULTRAVIOLET B RADIATION; COMPARATIVE STUDY; EVALUATION; MIDDLE AGED; PHOTOTHERAPY; PILOT STUDY; PSYCHOLOGICAL ASPECT;

ADULT; AGED; AGED, 80 AND OVER; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIBODIES, MONOCLONAL; FEMALE; HUMANS; IMMUNOGLOBULIN G; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; PILOT PROJECTS; PSORIASIS; QUALITY OF LIFE; RECEPTORS, TUMOR NECROSIS FACTOR; STRESS, PSYCHOLOGICAL; ULTRAVIOLET THERAPY;

EID: 73349125817     PISSN: 0393974X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Lowes MA, Bowcock AM, Krueger JG. Pathogenesis and therapy of psoriasis. Nature 2007; 445:866-873
2. Mastrolonardo M, Alicino D, Zeffirino R, Pasquini P, Picardi A. Effect of psychological stress on salivary interleukin-1beta in psoriasis. Arch Med Res 2007; 38:206-211 (Pubitemid 46080542)
3. Buske-Kirschbaum A, Ebrecht M, Kern S, Hellhammer DH. Endocrine stress responses in TH1-mediated chronic inflammatory skin disease (psoriasis vulgaris) - Do they parallel stress-induced endocrine changes in TH2-mediated inflammatory dermatoses (atopic dermatitis)? Psychoneuroendocrinology 2006; 31:439-446
4. Gilhar A, Yaniv R, Assy B, Serafimovich S, Ullmann Y, Kalish RS. Fas pulls the trigger on psoriasis. Am J Pathol 2006; 168:170-175
5. Fortune DG, Richards HL, Main CJ, Griffiths CE. Patients' strategies for coping with psoriasis. Clin Exp Dermatol 2002; 27:177-184
6. Katugampola RP, Hongbo Y, Finlay AY. Clinical management decisions are related to the impact of psoriasis on patient-rated quality of life. Br J Dermatol 2005; 152:1256-1262. Erratum in: Br J Dermatol 2005; 153:1092. (Pubitemid 40933426)
7. Fortune DG, Richards HL, Griffiths CE, Main CJ. Targeting cognitive-behaviour therapy to patients' implicit model of psoriasis: results from a patient preference controlled trial. Br J Clin Psychol 2004; 43:65-82.
8. Picardi A, Abeni D, Melchi CF, Puddu P, Pasquini P. Psychiatric morbidity in dermatological outpatients: an issue to be recognized. Br J Dermatol 2000; 143: 983-991
9. Papp KA. The long term efficacy and safety of new biological therapies for psoriasis. Arch Dermatol Res 2006; 298:7-15.
10. Van de Kerkhov PCM. Consistent control of psoriasis by continuous long-term therapy: the promise of biological treatments. J Eur Acad Derm Venereol 2006; 20:639-650 (Pubitemid 43919124)
11. Chong BF, Wong HK. Immunobiologics in the treatment of psoriasis. Clin Immunol 2007; 123:129-138
12. Cather JC, Menter A. Modulating T cell responses for the treatment of psoriasis: a focus on efalizumab. Expert Opin Biol Ther 2003; 5:361-370 (Pubitemid 36458765)
13. Boehncke WH, Brasie RA, Barker J, et al. European Dermatology Expert Group Recommendation for the use of etanercept in psoriasis: a European dermatology expert group consensus. J Eur Acad Dermatol Venereol 2006; 20:988-998 (Pubitemid 44241389)
14. Sampogna F, Sera F, Abeni D. Measures of clinical severity, quality of life, and psychological distress in patients with psoriasis: a cluster analysis. J Invest Dermatol 2004; 122:602-607 (Pubitemid 38471324)
15. Psocare report 2007, accessed 25 October 2008. http://www.psocare.it/cms/ system/files/u3/PSOCARE-2report-m.pdf
16. Gisondi P, Girolomoni G. Aggiornamento sui trattamenti biologici della psoriasi. G Ital Dermatol Venereol 2007; 142:1-11.
17. Ibbotson SH, Bilsland D, Cox NH, et al; British Association of Dermatologists. An update and guidance on narrowband ultraviolet B phototherapy: a British Photodermatology Group Workshop Report. Br J Dermatol 2004; 151:283-286
18. Gupta MA, Gupta AK. The Psoriasis Life Stress Inventory: a preliminary index of psoriasis-related stress. Acta Derma Venereol 1995; 75:240-243
19. Fortune DG, Main CJ, O'Sullivan TM, Griffiths CE. Assessing illness-related stress in psoriasis: the psychometric properties of the psoriasis life stress inventory. J Psychosom Res 1997; 42:467-475
20. Gupta MA. Psoriasis Life Stress Inventory - An index of the stress associated with the impact of psoriasis on the quality of life. In Care Management of Skin Disorders: Life quality and economic impact Rajagopalan R, Sheretz EF, Anderson RT eds. New York, Marcel Dekker, 1998, pp 147-151
21. Koo J, Lebwohl M. Duration of remission of psoriasis therapies. J Am Acad Dermatol 1999; 41:51-59